Drug intelligence / Profile preview

ezetimibe + cyclosporine

Development stage
Preclinical
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

**Ezetimibe + cyclosporine** is a combination of two pharmaceutical agents that are sometimes co-administered in clinical practice but is not a fixed-dose combination product. Ezetimibe is an intestinal cholesterol absorption inhibitor that acts at the brush border of the small intestine, reducing the absorption of cholesterol, leading to decreased plasma cholesterol levels. Cyclosporine is an immunosuppressant that primarily inhibits calcineurin, thereby suppressing T-cell activation and cytokine production. The co-administration of ezetimibe and cyclosporine is clinically significant due to a documented pharmacokinetic interaction: cyclosporine can dramatically increase plasma concentrations of ezetimibe (by 2.3–12 fold), raising the risk of ezetimibe toxicity. Ezetimibe can also modestly increase cyclosporine concentrations. This combination may be encountered in transplant patients with hyperlipidemia, but requires careful monitoring and dose adjustment due to these interactions[1][2][3][4][5][6].

Brand names
ZetiaNeoralSandimmuneGengraf
Other names
ezetimibecyclosporinecyclosporin A
02

Targets

CN (Calcineurin)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on ezetimibe + cyclosporine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ezetimibe + cyclosporine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call